United Therapeutics Corp (NASDAQ: UTHR) has terminated the Phase 3 PERFECT study evaluating Tyvaso (treprostinil) Inhalation Solution for pulmonary hypertension associated with chronic obstructive pulmonary disease.
The company terminated the study based on a recommendation of the study's independent Data Safety Monitoring Committee (DSMC), following a routine safety and efficacy analysis conducted by the DSMC.
The company will review the study's available data and plan to share the results with the scientific community.
According to clinicaltrials.gov, the trial was expected to conclude in 2024.
In its Q2 earnings release, United Therapeutics disclosed it decided to trigger a pre-specified transition and convert the PERFECT study from a crossover study into a single treatment period of 12 weeks.
Price Action: UTHR shares are down 3.44% at $209.42 on the last check Tuesday.
See more from Benzinga
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.